ClinicalTrials.gg
Active, not recruitingNCT06087458JOURNEYUpdated Nov 5, 2026

Phase 1/2 Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

A Phase 1/2 interventional study of VOY-101 in Age-Related Macular Degeneration, Geographic Atrophy and Non-neovascular AMD, sponsored by Perceive Biotherapeutics, Inc.. Active, not recruiting at 16 sites in 3 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Primary conditionGeographic AtrophyRegistry: Macular DegenerationReclassifiedWhy we changed it
Registry
Macular Degeneration — the first condition term the registry derived for this study.
ClinicalTrials.gg
Geographic Atrophy
Why
  1. The study's listed conditions name Geographic Atrophy, a narrower term within Macular Degeneration.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Perceive Biotherapeutics, Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jun 2023, registered Oct 2023).
Updated Nov 5, 2026Title changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.

Planned enrollment
65th of 107
60 · median 98
Started
2023
with 11 others
Phase 1/2
17 of 131
7 open now
Primary completion
2027-10
later than 17 of 44 live
Registered
95th of 131
by date

Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 65th largest by planned enrollment of the 107 interventional ones that give a count, is one of 12 that started in 2023, is one of 17 in phase 1/2, reaches primary completion later than 17 of the 44 other live ones, and was the 95th registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Geographic Atrophy studies recruiting now, 32 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 5 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Geographic Atrophy with a site in United States, or all of them as a file.
02

Study summary

The Phase 1 safety study of VOY-101 is comprised of escalating dose Cohorts, followed by a Phase 2 at the recommended phase 2 dose.

Read the detailed description

The study has a prospective, open-label, multi-center, two-part design to evaluate a single, unilateral intravitreal (IVT) injection of VOY-101 in subjects with geographic atrophy (GA), the advanced form of non-neovascular age-related macular degeneration (AMD). Phase 1 followed a standard dose escalation model to establish safety and tolerability of VOY-101 and determine the recommended phase 2 dose. This dose is being used in the randomized Phase 2 part of the study to evaluate the safety and efficacy of VOY-101 in the study eye compared to untreated fellow eye.

03

Conditions studied

  • Age-Related Macular Degeneration
  • Geographic Atrophy
  • Non-neovascular AMD
  • Non-neovascular Age-related Macular Degeneration

Browse trials for

04

In context

Geographic Atrophy Reclassified

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

This study's planned enrollment of 60 is below the median of 70 across 141 interventional studies indexed under Geographic Atrophy.

Browse Geographic Atrophy studies →

Lead sponsor

Perceive Biotherapeutics, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Compared within Geographic Atrophy, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are ≥60 years of age at the time of consent.
  • Are willing and able to understand and provide written .
  • Are willing and able to return for scheduled treatment and follow-up examinations.
  • Are able to undergo ETDRS BCDVA testing and ophthalmic imaging.
  • Well-demarcated GA secondary to AMD in the absence of MNV and in the absence of history of MNV for both eyes.
  • Absence of signs of non-exudative MNV.
  • Additional Ocular Inclusion Criteria for both eyes.
  • Meet certain genotype criteria for risk of AMD.

Exclusion criteria

Exclusion Criteria:

  • Are women of (WOCBP) and are pregnant or unwilling to use and document use of effective for the duration of the study.
  • Additional Systemic, Ocular, and Genetic Exclusion Criteria.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Low

    Single, unilateral, intravitreal injection of low dose of VOY-101

    Biological: VOY-101

  • Experimental
    Medium

    Single, unilateral, intravitreal injection of medium dose of VOY-101

    Biological: VOY-101

  • Experimental
    High

    Single, unilateral, intravitreal injection of high dose of VOY-101

    Biological: VOY-101

  • Experimental
    Higher

    Single, unilateral, intravitreal injection of higher dose of VOY-101

    Biological: VOY-101

  • Experimental
    Intermediate

    Single, unilateral, intravitreal injection of intermediate dose of VOY-101

    Biological: VOY-101

Interventions

  • BiologicalVOY-101

    VOY-101

07

What researchers measure

Primary outcomes

  1. Phase 1: To evaluate the safety and tolerability of a single intravitreal injection of escalating doses of VOY-101

    Frequency and type of ocular and systemic adverse events and non-serious treatment-emergent adverse events

    Time frame: 24 Months

  2. Phase 1: Change from Baseline in markers of inflammation

    Change from Baseline in markers of inflammation including anterior chamber cells, vitreous cells, and retinal vasculitis and retinitis.

    Time frame: Baseline to Month 24

  3. Phase 1: Establish the recommended Phase 2 dose in subjects with Geographic Atrophy.

    Determine whether the maximum tolerated dose (MTD) has been reached (as determined by the occurrence of dose-limiting toxicities \[DLTs\]) and select the RP2D.

    Time frame: Month 12

  4. Phase 2: To evaluate the effect of VOY-101 in the study eye compared with untreated fellow eye on change in Geographic Atrophy lesion size.

    Change from Baseline in Geographic Atrophy lesion size

    Time frame: 15 Months

Secondary outcomes

  1. Phase 1: To evaluate the effect of VOY-101 on geographic atrophy lesion size and photoreceptors

    Growth rate of total geographic atrophy lesion size and photoreceptor change

    Time frame: Baseline through 24 Months

  2. Phase 1/2: To establish the pharmacokinetic (PK) profile of VOY-101.

    Change from Baseline for complement levels in aqueous humor

    Time frame: Baseline through 24 Months

  3. Phase 1/2: To evaluate the effect of VOY-101 on best corrected distance visual acuity

    Change from Baseline in Early Treatment Diabetic Retinopathy Study (ETDRS) BCDVA and Percentage of subjects with \<15 letters lost in BCDVA from Treatment

    Time frame: 24 Months

  4. Phase 1/2: Development of macular neovascularization

    Incidence, frequency, severity, and timing of development of macular neovascularization

    Time frame: Month 24

  5. Phase 2: To further characterize the ocular and systemic safety and tolerability of VOY-101

    Frequency of Investigational Product related ocular and systemic adverse events, adverse events of special interest and non-serious treatment-emergent adverse events.

    Time frame: 24 Months

  6. Phase 2: To evaluate the effect of VOY-101 in the study eye compared with untreated fellow eye on geographic atrophy lesion size and photoreceptors

    Change in geographic atrophy lesion size and rate of photoreceptor loss

    Time frame: Baseline through Month 24

  7. Phase 2: To evaluate the effect of VOY-101 on low luminance visual acuity

    Change from Baseline in the change in visual function using Early Treatment Diabetic Retinopathy Study (ETDRS) Low Luminance Visual (LLVA) vision test

    Time frame: Baseline through Month 24

08

Study locations

16 sites
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2023 (actual). Primary completion is estimated for Oct 2027, 52 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2023
First posted
Oct 17, 2023
StartActual
Jun 21, 2023
Primary completionEst.
Oct 2027
CompletionEst.
Jun 2028
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Title
Phase 1/2 Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Title Phase 1/2 Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06087458
Lead sponsor
Perceive Biotherapeutics, Inc.
Responsible party
Sponsor
First posted
Oct 17, 2023
Start date
Jun 21, 2023
Primary completion
Oct 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Nov 5, 2026

Study contacts

Anne Fung, MD
study director · Perceive Biotherapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion